4487-50-7

Basic information

• Product Name: 4-NITRO-PYRIDIN-2-YLAMINE
• Synonyms: 2-AMINO-4-NITROPYRIDINE 97%;2-PyridinaMine, 4-nitro-;4-NITROPYRIDIN-2-AMINE;4-NITRO-PYRIDIN-2-YLAMINE;2-AMINO-4-NITROPYRIDINE;2-Amino-4-nitropyridine97%;2-Pyridinamine,4-nitro-(9CI)
• CAS NO: 4487-50-7
• Molecular Formula: C₅H₅N₃O₂
• Molecular Weight: 139.11
• Product Categories: pharmacetical;pyridine;Pyridines;NITRO
• Mol File: 4487-50-7.mol
• Article Data: 6

Chemical Properties

• Melting Point: 96 °C
• Boiling Point: 339 °C at 760 mmHg
• Flash Point: 158.8 °C
• Appearance: /
• Density: 1.437 g/cm³
• Vapor Pressure: 9.49E-05mmHg at 25°C
• Refractive Index: 1.645
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.43±0.11(Predicted)
• CAS DataBase Reference: 4-NITRO-PYRIDIN-2-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-NITRO-PYRIDIN-2-YLAMINE(4487-50-7)
• EPA Substance Registry System: 4-NITRO-PYRIDIN-2-YLAMINE(4487-50-7)

Safety Data

• Hazard Codes: Xi
• Safety Statements: 22-24/25
• Hazardous Substances Data: 4487-50-7(Hazardous Substances Data)

Usage

Uses

4-Nitropyridin-2-amine is used to synthesize tetrahydronaphthalene Raf inhibitors.

InChI:InChI=1/C5H5N3O2/c6-5-3-4(8(9)10)1-2-7-5/h1-3H,(H2,6,7)

Upstream product

• 4487-49-4 N-(4-nitropyridin-2-yl)-acetamide 
• 942076-74-6 N-[(4-(methoxy)phenyl)methyl]-4-nitro-pyridin2-amine 
• 942076-73-5 N-(4-methoxybenzyl)-4-nitropyridin-2-amine 1-oxide 
• 4487-48-3 2-acetylamino-4-nitropyridine N-oxide 
• 52092-45-2 2-amino-4-nitropyridine N-oxide 
• 14432-16-7 2-chloro-4-nitropyridine-N-oxide 
• 2402-95-1 2-chloropyridine-N-oxide 
• 109-09-1 2-chloropyridine 

Downstream Products

• 4487-49-4 N-(4-nitropyridin-2-yl)-acetamide 
• 942076-75-7 N-(4-nitropyridin-2-yl)-cyclopropanecarboxamide 
• 1274816-90-8 N-[(2R)-7-((2-[(cyclopropylcarbonyl)amino]pyridin-4-yl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl]-3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzamide 
• 1274817-09-2 N-(4-([(7R)-7-amino-5,6,7,8-tetrahydronaphthalen-2-yl]oxy)pyridin-2-yl)cyclopropanecarboxamide 
• 1274817-11-6 N-[(2S)-7-((2-[(cyclopropylcarbonyl)amino]pyridin-4-yl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl]-3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzamide hydrochloride 
• 1274817-12-7 N-(4-([(7S)-7-amino-5,6,7,8-tetrahydronaphthalen-2-yl]oxy)pyridin-2-yl)cyclopropanecarboxamide 
• 1274816-95-3 7-(2-acetamidopyridin-4-yloxy)-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid 
• 942077-42-1 7-((2-[(cyclopropylcarbonyl)-amino]pyridin-4-yl)oxy)-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid 
• 942072-08-4 ((R)-N-[3-(aminomethyl)-5-(trifluoromethyl)phenyl]-7-(2-[(cyclopropylcarbonyl)amino]pyridin-4-yl)oxy)-1,2,3,4-tetrahydronaphthalene-2-carboxamide 
• 942073-62-3 ((S)-N-[3-(aminomethyl)-5-(trifluoromethyl)phenyl]-7-(2-[(cyclopropylcarbonyl)amino]pyridin-4-yl)oxy)-1,2,3,4-tetrahydronaphthalene-2-carboxamide 

Relevant articles and documents

Structural and vibrational investigation of 2-amino-4-nitropyridine crystal

The X-ray structure of 2-amino-4-nitropyridine was determined at room temperature. The crystal belongs to the P2(I)/c space group of the monoclinic system (Z = 4, a = 6.7290(10), b = 10.946(2), c = 9.060(2) A, β = 100.03(3) deg) and is built of layers parallel to the (102) crystallographic plane. The molecules in the layer are joined into centrosymmetric dimers by two N-H···N hydrogen bonds (N···N distance = 3.011(3) A), which form rings of C(i) symmetry. The other N-H bonds of the amino groups are involved in N-H···O hydrogen bonds with the oxygen atoms of the nitro groups (N···O distance = 3.054(3) A). These hydrogen bonds join the dimers into an infinite plane. The powder IR and Raman spectra (4000-80 cm-1) were measured for normal and deuterated crystals and are discussed with respect to the crystal structure. The N-H stretching vibrations behave as the stretching vibrations of two almost independent hydrogen bonds. Strong A(g)-A(u)-type splitting is observed for the stretching vibrations of the N-H···N type hydrogen bonds.

JANUS KINASE INHIBITOR

Disclosed are a series of Janus kinase inhibitors, and particularly discolsed are a compound or pharmaceutically acceptable salts thereof of Formula (I) and use thereof in the preparation of drugs for treating Janus kinase (JAK)-related diseases.

SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF

This invention provides compounds of formula (I): wherein R1a, R1, R2a, and R2b have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.